Sculptra is approved in the United States for the face. On the neck, the chest and the backs of the hands it is used off-label: a clinician may choose it there, but no FDA review has weighed evidence for those sites. Searches for Sculptra on the neck run at about 360 a month, with the hands, chest and knees each in the tens (clickstream estimates, October 2026). This page lays out what the label covers, which sites have studies, how large and how independent those studies are, and what has gone wrong, as of 17 October 2026. It is a record of evidence, not advice; the decision belongs with a licensed clinician.
What the US approvals cover
Sculptra (poly-L-lactic acid, PMA P030050) holds three US indications: nasolabial folds and other facial wrinkles (2009), fine lines and wrinkles in the cheek region (25 April 2023), and HIV-associated facial fat loss (2004). A search of FDA's approval database for any Sculptra supplement mentioning the hands, neck, chest or décolletage returned nothing on 17 October 2026. Its labeling asks that it be used by professionals trained in the approved indication, and asks for special care in patients with thin skin — a description that fits the neck and the backs of the hands. More on the product itself is on our Sculptra page.
For comparison, Radiesse gained an FDA indication for volume loss in the back of the hands on 4 June 2015 (supplement P050052/S049), after a dedicated hand trial, and on 31 March 2026 an indication for décolleté wrinkles in people 22 and older, using the product diluted 1:2 with saline (S162). Its side-effect record is on our page about Radiesse's side effects, and the diluted technique on hyperdilute Radiesse. Sculptra has no approved use on the hands or the chest.
The evidence, site by site
| Site | Strongest study found | People | Design and sponsor | What it reported |
|---|---|---|---|---|
| Chest (décolletage) | Joseph, Palm and colleagues 2026 (PMID 42235050; NCT05538728) | 30 women | Randomized between two dilutions (8 mL vs 17 mL), open-label, no untreated group; sponsor Galderma | ≥1-point improvement at month 9: 93.8% (8 mL) and 78.6% (17 mL); one treatment-related adverse event, none serious |
| Chest | Wilkerson and Goldberg 2018 (PMID 29119683) | 25 women aged 40–70 | Open-label, one vial at each of three sessions | Improved at 6 months: 90% by investigators, 57% by the women themselves |
| Neck and chest | Mazzuco and Hexsel 2009 (PMID 19438668) | 36 (21 photo-assessed) | Case series, Brazil | Improvement in 81–100% of the 21 photographed cases; 91.6% satisfied; one person (3%) with early nodules; results held at 18 months |
| Hands | Sadick, Anderson, Werschler 2008 (PMID 19016062) | not stated in the abstract | Retrospective data from three practices | Bruising, swelling and pain resolving in days; no papules or nodules reported |
| Hands | Rendon 2010 (PMID 21142738) | 1 | Case report; the patient was told it was not FDA-approved for hands | Correction held at least 18 months; no adverse events |
Two patterns stand out. The chest has the most structured data, but no study compared Sculptra with no treatment, so the share of improvement owed to the product rather than to rating, season or expectation is unknown; the gap between investigators' 90% and the women's own 57% in the 2018 study shows how much the rater matters. The hands have no prospective trial at all — the hand literature for poly-L-lactic acid is a single case, a practice review and several reviews that compare hand fillers.
A PubMed search for poly-L-lactic acid or Sculptra with hand terms returned 31 records, and with neck, chest or décolletage terms 29, on 17 October 2026; many are about the polymer in surgery, dentistry or drug delivery rather than cosmetic injection. A pilot trial of 10 people with neck laxity was registered in Thailand (NCT07689344) with a planned start of 1 September 2026 and was listed as not yet recruiting.
The safety record off the face
The largest safety data set is a 2026 retrospective review of 498 people treated on the body at nine US sites (Durairaj and colleagues, PMID 42004285). It is mostly about the buttocks — 60.3% of sessions were gluteal, 8.2% décolletage — so it says little about the neck or hands specifically. Bruising was the most common event (5.0%) and a nodule was recorded in one person (0.2%). Five of its authors also appear on the Galderma-sponsored chest study, which suggests the same sponsor; the paper's own funding statement is the place to confirm it.
The neck is where the warning signs cluster in the case literature. A 2022 report describes nodules on the front of the neck after poly-L-lactic acid and says injection there is off-label and "may cause a higher incidence of nodule formation" (PMID 35960980). That fits Sculptra's own labeling, which ties papules and nodules to superficial placement and thin skin, and describes nodules appearing one to fourteen months after injection, some needing surgical removal. There is no enzyme that dissolves poly-L-lactic acid. The face-based side-effect record is on our page about Sculptra's side effects.
What is not established
Whether Sculptra beats no treatment on any of these three sites in a controlled trial; how it compares on the hands and chest with Radiesse, the one biostimulator approved for both; how often nodules occur on the neck; and how long any effect lasts beyond 18 months. Other off-label sites are covered on our pages about Sculptra for the buttocks and Sculptra under the eyes and in the temples; topical products sold for the same area are covered in our peptide neck cream census. These are questions to put to a licensed clinician before any treatment.
Sources
Opened 17 October 2026: openFDA premarket-approval searches for P030050 (Sculptra) and P050052 (Radiesse; supplements S049, decision 4 June 2015, and S162, decision 31 March 2026); the Sculptra labeling filed with P030050/S039; ClinicalTrials.gov records NCT05538728 and NCT07689344; PubMed records 42235050, 42004285, 29119683, 19438668, 35960980, 19016062 and 21142738, and the searches stated (31 and 29 records). Corrections go to the contact page.